KalVista Pharmaceuticals, Inc.
$20.87
▲
0.66%
2026-04-21 07:41:01
www.kalvista.com
NGM: KALV
Explore KalVista Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.07 B
Current Price
$20.87
52W High / Low
$21.3 / $9.83
Stock P/E
—
Book Value
$-0.05
Dividend Yield
—
ROCE
-89%
ROE
-121.5%
Face Value
—
EPS
$-3.94
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
275
Beta
-0.4
Debt / Equity
0.07
Current Ratio
5.58
Quick Ratio
5.52
Forward P/E
19.28
Price / Sales
13.49
Enterprise Value
$977.2 M
EV / EBITDA
-5.93
EV / Revenue
13.27
Rating
Strong Buy
Target Price
$34.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
| 2. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
| 3. | Soligenix, Inc. | $1.38 | — | $14.22 M | — | -213.96% | -2.35% | $6.23 / $1 | $0.77 |
| 4. | Sana Biotechnology, Inc. | $3.82 | — | $939.37 M | — | -60.83% | -1.19% | $6.55 / $1.53 | $0.6 |
| 5. | NewcelX Ltd. | $2.83 | — | $12.13 M | — | 23.66% | 158.49% | $30.8 / $1.83 | $-11.28 |
| 6. | Nuvation Bio Inc. | $5.12 | — | $1.77 B | — | -41.57% | -53.18% | $9.75 / $1.57 | $0.88 |
| 7. | CAMP4 THERAPEUTICS CORPORATION | $4.51 | — | $233.12 M | — | -50.89% | -1.45% | $7.75 / $1.3 | $0.92 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 13.69 M | 1.43 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -46.05 M | -59.01 M | -50.02 M | -42.94 M | -45.81 M | — |
| Net Profit | -49.48 M | -60.1 M | -52.23 M | -48.51 M | -42.27 M | — |
| EPS in Rs | -0.97 | -1.17 | -1.02 | -0.95 | -0.83 | -0.87 |
Profit & Loss
Figures shown in M / B
| 2025 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Sales | — | 0 M | 0 M | 0 M |
| Operating Profit | — | -182.98 M | -131.99 M | -95.09 M |
| Net Profit | — | -183.44 M | -126.64 M | -92.91 M |
| EPS in Rs | — | -3.58 | -2.47 | -1.81 |
Balance Sheet
Figures shown in M / B
| 2025 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Total Assets | 335.38 M | 250.77 M | 235.4 M | 183.2 M |
| Total Liabilities | 338.09 M | 155.38 M | 28.82 M | 22.18 M |
| Equity | -2.71 M | 95.39 M | 206.58 M | 161.03 M |
| Current Assets | 320.15 M | 241.69 M | 225.69 M | 172.33 M |
| Current Liabilities | 57.35 M | 45.17 M | 22.81 M | 15.03 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -152.91 M | -89.23 M | -75.26 M | -78.13 M |
| Investing CF | 91.02 M | -84.72 M | 41.41 M | 57.86 M |
| Financing CF | 159.73 M | 150.71 M | 58.12 M | 1.58 M |
| Free CF | -153.84 M | -89.67 M | -76.46 M | -79.06 M |
| Capex | -0.93 M | -0.44 M | -1.2 M | -0.93 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -44.85% | -36.31% | -12.83% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.